Repository logo
 

Activation of the proton-sensing GPCR, GPR65 on fibroblast-like synoviocytes contributes to inflammatory joint pain.

Published version
Peer-reviewed

Repository DOI


Loading...
Thumbnail Image

Change log

Abstract

Inflammation is associated with localized acidosis, however, attributing physiological and pathological roles to proton-sensitive receptors is challenging due to their diversity and widespread expression. Here, agonists of the proton-sensing GPCR, GPR65, were systematically characterized. The synthetic agonist BTB09089 (BTB) recapitulated many proton-induced signaling events and demonstrated selectivity for GPR65. BTB was used to show that GPR65 activation on fibroblast-like synoviocytes (FLS), cells that line synovial joints, results in the secretion of proinflammatory mediators capable of recruiting immune cells and sensitizing sensory neurons. Intra-articular injection of BTB resulted in GPR65-dependent sensitization of knee-innervating neurons and nocifensive behaviors in mice. Stimulation of GPR65 on human FLS also triggered the release of inflammatory mediators and synovial fluid samples from human osteoarthritis patients were shown to activate GPR65. These results suggest a role of GPR65 in mediating cell-cell interactions that drive inflammatory joint pain in both mice and humans.

Description

Journal Title

Proc Natl Acad Sci U S A

Conference Name

Journal ISSN

0027-8424
1091-6490

Volume Title

Publisher

Proceedings of the National Academy of Sciences

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
BBSRC (1943916)
Biotechnology and Biological Sciences Research Council (1943916)
BBSRC (1943916)
MRC (MR/W002426/1)
BBSRC (BB/V509528/1)
Wellcome Trust (225856/Z/22/Z)
BBSRC Doctoral Training Programme (BB/MO11194/1) Corpus Christi College MRC (MR/W002426/1 & MR/W026961/1) AstraZeneca (G104108) BBSRC / GSK (BB/V509528/1) Wellcome Trust (225856/Z/22/Z) Versus Arthritis (21530) Royal Society (NF\R2\212001) From the paper: The authors acknowledge the following sources of funding to support this work: University of Cambridge BBSRC Doctoral Training Programme BB/MO11194/1 (LAP); Corpus Christi College, University of Cambridge Studentship (LAP); MRC Grant MR/W002426/1 (LAP, ESS); AstraZeneca PhD Studentship G104108 (RHR); BBSRC/GSK iCASE PhD Studentship BB/V509528/1 (HH); Wellcome Trust Grant 225856/Z/22/Z (MD, ESS); MRC Grant MR/W026961/1 (SNW, SWJ); Versus Arthritis Grant 21530 (SNW, SWJ); Royal Society Industry Fellowship NF\R2\212001 (GL).

Version History

Now showing 1 - 2 of 2
VersionDateSummary
2*
2024-12-12 11:11:26
Published version added
2024-11-23 00:31:16
* Selected version